| Phase | Design | Target Population | Primary Endpoint | Expected Milestones | |-------|--------|-------------------|------------------|---------------------| | Phase 1b/2a (dose‑finding, safety) | Open‑label, 3‑plus‑3 escalation → expansion cohorts | KRAS‑G12D+ solid tumors (pancreatic, colorectal, NSCLC) with RAF‑DimerScore ≥ 2 | ORR (RECIST v1.1) + safety | IND filing Q3 2024 → First patient in Q1 2025 | | Phase 2b (confirmatory) | Randomized, double‑blind, MEYD‑873 + standard chemo vs. chemo alone | Same as above | PFS, OS, and biomarker‑driven subgroup analysis | Topline data Q4 2026 | | Phase 3 (global pivotal) | Multi‑regional, double‑blind | KRAS‑G12D+/RAF‑high metastatic pancreatic adenocarcinoma (primary) and KRAS‑G12D+ NSCLC (secondary) | OS superiority | NDA submission Q2 2029 |
We have secured fast‑track and orphan‑drug designations from the FDA (2025) and EMA PRIME status (2025).
“When I was diagnosed with KRAS‑G12D pancreatic cancer, my oncologist told me the options were limited and the side effects were harsh. After enrolling in the MEYD‑873 early‑access trial, my scans showed a 70 % reduction in tumor size after just two months, and I felt better than I had in a year.”
— John D., 58, trial participant (fictional for illustration only) MEYD-873
While the above vignette is a composite, it reflects the hope we aim to bring to patients whose cancers harbor the same molecular fingerprints.
🚀 Introducing MEYD‑873 – the next‑generation solution that’s redefining [your industry/field]. Persistence mechanisms:
✅ Key Benefits
• [Benefit #1] – What it does and why it matters
• [Benefit #2] – Quick win for users
• [Benefit #3] – Long‑term impact🎉 Launch Date: [Insert Date]
🔗 Learn more: [Landing‑page URL] Data exfiltration:#MEYD873 #Innovation #TechRevolution #YourBrand #ComingSoon